✦ LIBER ✦

A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy

✍ Scribed by Hurvitz, Sara A.; Dalenc, Florence; Campone, Mario; OâRegan, Ruth M.; Tjan-Heijnen, Vivianne C.; Gligorov, Joseph; Llombart, Antonio; Jhangiani, Haresh; Mirshahidi, Hamid R.; Tan-Chiu, Elizabeth; Miao, Sara; El-Hashimy, Mona; Lincy, Jeremie; Taran, Tetiana; Soria, Jean-Charles; Sahmoud, Tarek; AndrÃ©, Fabrice

Book ID: 121419972
Publisher: Springer US
Year: 2013
Tongue: English
Weight: 327 KB
Volume: 141
Category: Article
ISSN: 0167-6806
DOI: 10.1007/s10549-013-2689-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase Ib Study of Buparlisib plus Trastu

Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy

✍ Saura, C.; Bendell, J.; Jerusalem, G.; Su, S.; Ru, Q.; De Buck, S.; Mills, D.; R 📂 Article 📅 2014 🏛 American Association for Cancer Research 🌐 English ⚖ 898 KB

5021 Everolimus (RAD001) in combination

5021 Everolimus (RAD001) in combination with weekly paclitaxel and trastuzumab in patients (pts) with HER-2-overexpressing metastatic breast cancer (MBC) with prior resistance to trastuzumab: a multicenter phase I clinical trial

✍ S. Hurvitz; R. O'Regan; M. Campone; C. Manlius; L. Vittori; P. Mukhopadhyay; C. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 49 KB

Phase II study of capecitabine and trast

Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes

✍ Takanori Ishida; Takayoshi Kiba; Motohiro Takeda; Kotone Matsuyama; Satoshi Tera 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 367 KB

Phase II evaluation of the efficacy and

Phase II evaluation of the efficacy and safety of trastuzumab plus pertuzumab therapy in patients with HER2-positive metastatic breast cancer that had progressed during trastuzumab treatment

✍ J. Cortes; K. Gelmon; P. Fumoleau; A. Wardley; S. Verma; P.F. Conte; L. Gianni; 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 58 KB

5004 Multicenter phase I clinical trial

5004 Multicenter phase I clinical trial of daily and weekly everolimus (RAD001) in combination with vinorelbine and trastuzumab in patients with HER-2-overexpressing metastatic breast cancer (MBC) with prior resistance to trastuzumab

✍ F. Cardoso; L. Gianni; G. Jerusalem; A. Fasolo; J. Bergh; V. Dieras; C. Manlius; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 50 KB

Combination docetaxel and trastuzumab tr

Combination docetaxel and trastuzumab treatment for patients with her-2-overexpressing metastatic breast cancer: A multicenter, phase-II study

✍ Nobuaki Sato; Muneaki Sano; Toshio Tabei; Taro Asaga; Jiro Ando; Hirofumi Fujii; 📂 Article 📅 2006 🏛 Springer Japan 🌐 English ⚖ 553 KB